drugset / Trial / NCT05938036
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
RandomizedParallel-groupDouble-blindTreatment
Summary
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2027-05-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALT-100 | Monoclonal antibody | 0.4 mg/kg | Intravenous |
| Subject | ALT-100 | Monoclonal antibody | 1 mg/kg | Intravenous |